Emerging viral infections--a potential threat for blood supply in the 21st century.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- de Mendoza C
- Altisent C
- Batlle J
Abstract
During the last 25 years the safety of blood products has improved dramatically with regard to infectious risk, notably to the threat represented by retroviruses (HIV and human T-cell lymphotropic virus) and hepatitis B and C viruses. However, both residual and emergent viral infections are still responsible for contaminations in recipients of blood products. Along with other viruses (human herpesvirus-8, human parvovirus B19, hepatitis A and E viruses, etc.), special attention has recently been paid to emerging arboviruses, such as West Nile virus in North America, and Dengue and Chikungunya viruses in Europe. Another blood-linked risk, notably in the United Kingdom and France, is the prion agent responsible for the variant form of the Creutzfeldt-Jakob disease. Hemophilia care has been the model for improvements in the safety and availability of safe blood components free of infectious agents. In this regard, several measures aimed to halt transmission of viruses have been implemented in blood banks, including the exclusion of at-risk donors, specific sensitive diagnostic tests, leukocyte reduction of labile blood products, and the physical or chemical treatments aiming at nonspecific inactivation of infectious agents potentially present in blood without impairing significantly its physiological properties.
Filiaciones
Proyectos asociados
ESTUDIO ABIERTO DE SEGURIDAD Y SOBRE LA EFICACIA DE REFACTO AF EN PACIENTES NO TRATADOS PREVIAMNTE, EN CONDICIONES ASISTENCALES HABITUALES.
Investigador Principal: ANA ROSA CID HARO
3082B2-4434-WW . 2010
ESTUDIO DE INDUCCION DE INMUNOTOLERANCIA EN PACIENTES CON HEMOFILIA A GRAVE CON INHIBIDOR TRAS FRACASO PREVIO EN INDUCCION DE INMUNOTOLERANCIA UTILIZANDO CONCENTRADOS DE FVIII SIN FACTOR VON WILLEBRAND.
Investigador Principal: SATURNINO HAYA GUAITA
RESIST-EXPERIENCED . 2010
SEGURIDAD Y EFICACIA DE N8 EN LA PREVENCION Y EL TRATAMIENTO A DEMANDA DE EPISODIOS HEMORRAGICOS EN SUJETOS CON HEMOFILIA A . SUBESTUDIO: EFICACIA Y SEGURIDAD DE N8 EN LA PREVENCION Y EL TRATAMIENTO DE LA HEMORRAGIA DURANTE LOS PROCEDIMIENTOS QUIRURGICO S EN SUJETOS CON HEMOFILIA A.
Investigador Principal: ANA ROSA CID HARO
NN7008-3568 . 2010
UN ESTUDIO EUROPEO, NO INTERVENCIONAL, LONGITUDINAL, SOBRE LA CALIDAD DE VIDA EN RELACION CON LA SALUD Y LA IDENTIDFICACION DE LOS HECHOS CLAVES EN LOS CAMBIOS DE LAS CONDICIONES DE VIDA DE PACIENTES CON HEMOFILIA A , DE MODERADA A GRAVE, TRATADOS CON HEL IXATE NEXGEN
Investigador Principal: ANA ROSA CID HARO
CSL-FAC-2009-01 . 2010
ESTUDIO DE LA INCIDENCIA DE HEMARTROSIS EN EL PACIENTE HEMOFÍLICO ADULTO GRAVE CON PROFILAXIS SECUNDARIA.
Investigador Principal: JOSE ANTONIO AZNAR LUCEA
PROFILHEMA
CARACTERIZACIÓN DE LOS INHIBIDORES EN PACIENTES CON DIAGNÓSTICO DE HEMOFILIA ADQUIRIDA
Investigador Principal: JOSE ANTONIO AZNAR LUCEA
SET-INM-2010-01
Cita
de Mendoza C,Altisent C,Aznar JA,Batlle J,Soriano V. Emerging viral infections--a potential threat for blood supply in the 21st century. AIDS REV. 2012. 14. (4):p. 279-289. IF:4,075. (1).